Investigators fault Lilly plant for manufacturing issues
Want to stay on top of the science and politics driving biotech today? Sign up to get…
Category: Pharma
STAT+: In ‘march-in’ rights, some see a tool to lower drug prices. Others see a threat to intellectual property
In the fall of 2020, Robert Sachs was prescribed a medication to treat prostate cancer…
STAT+: FDA scolds Novartis over a misleading TV ad for a breast cancer treatment
The U.S. Food and Drug Administration scolded Novartis for making false and misleading statements about…
STAT+: Pharmalittle: We’re reading about Sanders targeting pharma CEOs, insider trading, and more
And so, another working week will soon draw to a close. Not a moment too…
The Senate health committee looks into its first subpoena in 40 years
Want to stay on top of the science and politics driving biotech today? Sign up to get…
STAT+: Klobuchar urges drugmakers to remove patents FTC calls improper and inaccurate
Amid a push to crack down on patent abuse by the pharmaceutical industry, a key…
STAT+: Bernie Sanders proposes subpoenas of CEOs of J&J, Merck on drug prices
WASHINGTON — Senate health committee chair Bernie Sanders has taken a step toward subpoenaing the…
The XBI comedown after JPM
Want to stay on top of the science and politics driving biotech today? Sign up to get…
STAT+: Pharmalittle: We’re reading about drug price hikes, Bayer strategic moves, and more
Rise and shine, everyone, another busy day is on the way. Sadly, gray skies are…
The big any-day-now biotech news we’re keeping an eye on
Want to stay on top of the science and politics driving biotech today? Sign up to get…
STAT+: Pharmalittle: We’re reading about a CRISPR approval, selling meds directly to patients, and more
Rise and shine, everyone. The middle of the week is upon us. Have heart, though….
STAT+: More patients are getting their meds online. Big Pharma wants in on the action
Since the pandemic, patients have become increasingly comfortable with getting their medications online. Direct-to-consumer telehealth…
.jpg)
STAT+: Survey: Confusion over key requirements means clinical trials aren’t registered and results aren’t reported
More than half of those responsible for registering clinical trials and reporting results fail to…
STAT+: Pharmalittle: We’re reading about Wegovy shipments, the NIH director’s plans, and more
Good morning, everyone, and welcome to another working week. We hope the weekend respite —…
The four biotech stories you need to read this morning
Want to stay on top of the science and politics driving biotech today? Sign up to get…
Novartis reportedly decides to pass on Cytokinetics
Want to stay on top of the science and politics driving biotech today? Sign up to get…
STAT+: New congressional bill would thwart patent thickets in order to speed generic drugs to market
In the latest bid to lower the cost of medicines, a new bill was introduced…
STAT+: Pharmalittle: We’re reading about GLP-1 drugs’ safety, Novartis nixing a deal, and more
And so, another working week will soon come to a close. Not a moment too…
The highs — and lows — of JPM 2024 you should pay attention to
In honor of JPM Week, you’re reading a special edition of our biotech newsletter, The…
STAT+: Pharmalittle: We’re reading about FDA’s syphillis-drug plan, India’s manufacturer-inspection demands, and more
Rise and shine, another busy day is on the way. However, this is also shaping…
STAT+: Contributors to psychiatry’s bible, the DSM-5, got $14 million from industry
Amid ongoing concerns over conflicts of interest, a new study found that 60% of the…
.jpg)
JPM Day 3 had a cautiously optimistic outlook
In honor of JPM Week, you’re reading a special edition of our biotech newsletter, The…
STAT+: Pharmalittle: We’re reading about Sanofi’s Olympics bet, Singulair problems, and more
Good morning, everyone, and how are you today? We are doing just fine, thank you….
STAT+: Bayer’s promising menopause drug trial results highlight growing interest in long-neglected condition
More hopeful news on the menopause front: Bayer announced on Monday encouraging results in two…
JPM Day 2 has arrived. Here are the can’t-miss moments of the event so far
In honor of JPM Week, you’re reading a special edition of our biotech newsletter, The…
STAT+: Pharmalittle: We’re reading about a GSK deal, a probe into inhaler prices, and more
Rise and shine, everyone, another busy day is on the way. We can tell by…
This is the TLDR of JPM Day 1
In honor of JPM Week, you’re reading a special edition of our biotech newsletter, The…
STAT+: Florida faces ‘complicated road’ before actually importing drugs from Canada, expert says
Last week, the Food and Drug Administration granted Florida permission to import medicines from Canada,…
STAT+: Sen. Sanders, others lawmakers open probe into asthma inhaler makers over pricing, patent maneuvers
Several U.S. lawmakers including Sen. Bernie Sanders (I-Vt.) are investigating the prices charged by four…
STAT+: Pharmalittle: We’re reading about LillyDirect, India’s drug standards, and more
Good morning, everyone, and welcome to another working week. We hope the weekend respite was…
No pain data yet from Vertex, and sky high deal expectations at JPM 2024
Want to stay on top of the science and politics driving biotech today? Sign up to…
Biden’s FDA is letting Ron DeSantis import cheaper drugs from Canada. Who gets to take credit?
WASHINGTON — The Biden administration has approved Florida Gov. Ron DeSantis’ plan to import a…
STAT+: GSK is replacing its popular Flovent inhaler with authorized generics, raising cost concerns for asthma patients
As of Jan. 1, thousands of asthma patients in the U.S. will no longer be…
Why did Allogene cancel two clinical trials for its off-the-shelf cell therapy?
Want to stay on top of the science and politics driving biotech today? Sign up to get…
STAT+: Pharmalittle: We’re reading about Lilly selling drugs directly, UCB leaving BIO, and more news
And so, another working week will soon come to a close. Not a moment too…
STAT+: Another major pharma company departs BIO
WASHINGTON — UCB left BIO at the end of 2023, the second major member company to…
STAT+: FDA is blasted by advocates for pursuing a deal with data provider that has ties to opioid makers
Several advocacy groups are blasting a Food and Drug Administration proposal to work with a…
Why CG Oncology will be the first test of 2024’s IPO waters
Want to stay on top of the science and politics driving biotech today? Sign up to get…
STAT+: Pharmalittle: We’re reading about CVS dropping Humira coverage, pharma layoffs, and more
Rise and shine, everyone, another busy day is on the way. Sadly, gray skies are…
Anavex’s slow journey to failure
Want to stay on top of the science and politics driving biotech today? Sign up to get…
STAT+: Pharmalittle: FDA approvals rebound, abortion pill orders rise, and more news
Hello, everyone, and how are you today? We are doing fine, thank you, especially given…
STAT+: Consumer health advocate Sid Wolfe was a thorn in the side. We’re all the better as a result
The first phone call came some time in late 1996. “Ed, I’d like to introduce…
STAT+: Pharmalittle: Drugmakers raise prices, pharmacies fear fees, McKinsey settles
Good morning, everyone, and welcome to another working week, and a new year, as well….
STAT+: 3 FDA staffers to watch in 2024
WASHINGTON — The Food and Drug Administration has a lot on its plate in 2024…
STAT+: 3 issues to watch in pharma in 2024
As another year comes to an end and the world seems to hit the proverbial…
STAT+: Bristol Myers will pay $4.1 billion for cancer startup RayzeBio
Bristol Myers Squibb will pay $4.1 billion for RayzeBio, the companies said Tuesday, buying into…
STAT+: Venture capital is still pouring into drug research despite Medicare price negotiation
WASHINGTON — Venture capitalists are still pouring money into drug research in spite of Medicare’s…
The clock is ticking, and cytokinetics is running out of December
Want to stay on top of the science and politics driving biotech today? Sign up to get…
STAT+: Pharmalittle: Bristol Myers to buy schizophrenia-drug maker; Servier found guilty of fraud
And so, another working week will soon come to a close. Not a moment too…
STAT+: Bristol Myers to purchase Karuna, maker of schizophrenia drug, for $14 billion
Bristol Myers Squibb said Friday that it will acquire Karuna Therapeutics, a developer of medicines…